Pfizer says IRA impact will be ‘modest,’ maps out R&D priority changes

De­spite be­ing an ear­ly crit­ic of the In­fla­tion Re­duc­tion Act, Pfiz­er told in­vestors on Mon­day that the leg­is­la­tion is like­ly to have a “mod­est” im­pact on the com­pa­ny over­all.

Pfiz­er’s CEO Al­bert Bourla was one of sev­er­al phar­ma ex­ec­u­tives to con­demn the IRA’s Medicare ne­go­ti­a­tion pro­vi­sions ear­ly on, call­ing it “ne­go­ti­a­tion with a gun to your head” in a live-streamed Reuters in­ter­view last May. But it ap­pears that Pfiz­er is com­ing to terms with the new law.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.